Call for panel nominations
This article was originally published in The Tan Sheet
Nominations for voting consumer representatives on CDER advisory committees will be accepted until the end of the year, FDA says in an April 13 Federal Register notice. Spots on the Nonprescription Drugs, Metabolic & Endocrinologic Drugs, Arthritis Drugs, Pulmonary-Allergy Drugs, Cardiovascular & Renal Drugs and Anti-Infective Drugs are open. Nominations should include a cover letter, CV or resume, and list of community or consumer groups in which the candidate is involved; self nominations will be accepted, FDA notes...
You may also be interested in...
With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?